Medasense, a pain management technology company, today announced a strategic partnership with Nihon Kohden for exclusive distribution of its pain monitoring device in Japan, pending regulatory approval. The partnership will introduce Medasense’s nociception monitor to the market.Its nociception monitor is a device which includes an AI powered NOL - Nociception Level Index, and real-time objective pain monitoring to personalize and optimize pain treatment.

疼痛管理技术公司Medasense今天宣布与日本Kohden建立战略合作伙伴关系，在日本独家分销其疼痛监测设备，等待监管部门的批准。该合作伙伴关系将向市场推出Medasense的伤害感受监测仪。它的伤害感受监护仪是一种设备，包括人工智能驱动的伤害感受水平指数和实时客观疼痛监测，以个性化和优化疼痛治疗。

The NOL - Nociception Level Index quantifies the physiological response to pain, according to the company press release, with over 40 peer reviewed publications and clinical studies demonstrating “that NOL-guided analgesia resulted in intraoperative opioid sparing, and improved post-operative pain score and patient recovery.”Its flagship product, the PMD-200 — commercially available in the US, Europe, Canada, Latin America, and Israel — uses this index, leveraging its advanced AI and proprietary non-invasive sensor system to objectively measure pain in patients in operating room or critical care settings unable to communicate.Through the strategic agreement, the monitor will be accessible to hospitals and clinics throughout Japan using Nihon Kohden’s distribution channels, pending regulatory approval.“We are honored to partner with Nihon Kohden, a company with a long history of excellence, that shares our vision of improving patient care through innovative solutions,” said Galit Zuckerman Medasense CEO and founder, in the release.

根据该公司的新闻稿，NOL伤害感受水平指数量化了对疼痛的生理反应，超过40篇同行评审的出版物和临床研究表明“NOL引导的镇痛导致术中阿片类药物的保留，并改善了术后疼痛评分和患者恢复。”其旗舰产品PMD-200（在美国，欧洲，加拿大，拉丁美洲和以色列上市）使用该指数，利用其先进的AI和专有的非侵入性传感器系统客观地测量手术室或重症监护环境中无法沟通的患者的疼痛。通过这项战略协议，在监管部门批准之前，日本全日本的医院和诊所将可以通过日本Kohden的分销渠道使用该监护仪。Galit Zuckerman Medasense首席执行官兼创始人Galit Zuckerman Medasense在新闻稿中表示：“我们很荣幸与Nihon Kohden合作，这是一家拥有悠久卓越历史的公司，与我们分享通过创新解决方案改善患者护理的愿景。”。

' Our mission is to help all patients suffer less from pain and the adverse effects of pain medication. Nihon Kohden's established clinical, technological leadership and expertise in the Japanese market make them the perfect partner to distribute our nociception monitor.'.

“我们的使命是帮助所有患者减轻疼痛和止痛药的不良反应。日本Kohden在日本市场建立的临床、技术领先地位和专业知识使其成为分销我们伤害感受监测仪的完美合作伙伴。”。